Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus

M. Hummel, I. Durinovic-Bello, E. Bonifacio, V. Lampasona, J. Endl, S. Fessele, F. Then Bergh, C. Trenkwalder, E. Standl, A. G. Ziegler

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives - Humoral and cellular immune reactivity are reported for two neuroendocrine autoantigens - glutamic acid decarboxylase (GAD) and the protein tyrosine phosphatase IA-2 - in a patient with the autoimmune type of stiff-man syndrome and insulin dependent diabetes (IDDM). Methods - Antibodies and T cell proliferation against GAD and IA-2 and cytokine release of antigen stimulated T cells (IFN-γ) were determined before and several times during immunosuppressive therapy with prednisolone. Results - Raised GAD antibodies against full length GAD65 or chimeric constructs were detected before therapy and they remained at a high concentration despite a marked clinical improvement during cortisone treatment. Antibodies to IA-2 were undetectable, but weak T cell responses to both GAD and IA-2 were seen before therapy and once on reduction of high cortisone dosages when the patient showed signs of clinical deterioration. Cytokine profiles showed increased IFN-γ production after stimulation with GAD or IA-2 suggesting increased activation of T(H)1 cells. Conclusion - Immunosuppressive therapy - even with extremely high doses of 500 mg a day - does not lead to the reduction of antibody concentrations in the periphery nor to a switch in epitope recognition of such antibodies despite clinical improvement. The amount of T cell reactivity to various antigens, however, may be a useful marker to monitor the effectiveness of immunotherapy.

Original languageEnglish
Pages (from-to)204-208
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume65
Issue number2
Publication statusPublished - Aug 1998

Fingerprint

Stiff-Person Syndrome
Glutamate Decarboxylase
Immunosuppressive Agents
Type 1 Diabetes Mellitus
T-Lymphocytes
Antibodies
Cortisone
Class 8 Receptor-Like Protein Tyrosine Phosphatases
Cytokines
Therapeutics
Antigens
Autoantigens
Prednisolone
Immunotherapy
Epitopes
Cell Proliferation
Insulin

Keywords

  • Autoantibodies
  • Prednisolone therapy
  • Stiff-man syndrome
  • T cell reactivity

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. / Hummel, M.; Durinovic-Bello, I.; Bonifacio, E.; Lampasona, V.; Endl, J.; Fessele, S.; Then Bergh, F.; Trenkwalder, C.; Standl, E.; Ziegler, A. G.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 65, No. 2, 08.1998, p. 204-208.

Research output: Contribution to journalArticle

Hummel, M, Durinovic-Bello, I, Bonifacio, E, Lampasona, V, Endl, J, Fessele, S, Then Bergh, F, Trenkwalder, C, Standl, E & Ziegler, AG 1998, 'Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus', Journal of Neurology, Neurosurgery and Psychiatry, vol. 65, no. 2, pp. 204-208.
Hummel, M. ; Durinovic-Bello, I. ; Bonifacio, E. ; Lampasona, V. ; Endl, J. ; Fessele, S. ; Then Bergh, F. ; Trenkwalder, C. ; Standl, E. ; Ziegler, A. G. / Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus. In: Journal of Neurology, Neurosurgery and Psychiatry. 1998 ; Vol. 65, No. 2. pp. 204-208.
@article{e5d2101c9be14514bcfc797098a24d39,
title = "Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus",
abstract = "Objectives - Humoral and cellular immune reactivity are reported for two neuroendocrine autoantigens - glutamic acid decarboxylase (GAD) and the protein tyrosine phosphatase IA-2 - in a patient with the autoimmune type of stiff-man syndrome and insulin dependent diabetes (IDDM). Methods - Antibodies and T cell proliferation against GAD and IA-2 and cytokine release of antigen stimulated T cells (IFN-γ) were determined before and several times during immunosuppressive therapy with prednisolone. Results - Raised GAD antibodies against full length GAD65 or chimeric constructs were detected before therapy and they remained at a high concentration despite a marked clinical improvement during cortisone treatment. Antibodies to IA-2 were undetectable, but weak T cell responses to both GAD and IA-2 were seen before therapy and once on reduction of high cortisone dosages when the patient showed signs of clinical deterioration. Cytokine profiles showed increased IFN-γ production after stimulation with GAD or IA-2 suggesting increased activation of T(H)1 cells. Conclusion - Immunosuppressive therapy - even with extremely high doses of 500 mg a day - does not lead to the reduction of antibody concentrations in the periphery nor to a switch in epitope recognition of such antibodies despite clinical improvement. The amount of T cell reactivity to various antigens, however, may be a useful marker to monitor the effectiveness of immunotherapy.",
keywords = "Autoantibodies, Prednisolone therapy, Stiff-man syndrome, T cell reactivity",
author = "M. Hummel and I. Durinovic-Bello and E. Bonifacio and V. Lampasona and J. Endl and S. Fessele and {Then Bergh}, F. and C. Trenkwalder and E. Standl and Ziegler, {A. G.}",
year = "1998",
month = "8",
language = "English",
volume = "65",
pages = "204--208",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus

AU - Hummel, M.

AU - Durinovic-Bello, I.

AU - Bonifacio, E.

AU - Lampasona, V.

AU - Endl, J.

AU - Fessele, S.

AU - Then Bergh, F.

AU - Trenkwalder, C.

AU - Standl, E.

AU - Ziegler, A. G.

PY - 1998/8

Y1 - 1998/8

N2 - Objectives - Humoral and cellular immune reactivity are reported for two neuroendocrine autoantigens - glutamic acid decarboxylase (GAD) and the protein tyrosine phosphatase IA-2 - in a patient with the autoimmune type of stiff-man syndrome and insulin dependent diabetes (IDDM). Methods - Antibodies and T cell proliferation against GAD and IA-2 and cytokine release of antigen stimulated T cells (IFN-γ) were determined before and several times during immunosuppressive therapy with prednisolone. Results - Raised GAD antibodies against full length GAD65 or chimeric constructs were detected before therapy and they remained at a high concentration despite a marked clinical improvement during cortisone treatment. Antibodies to IA-2 were undetectable, but weak T cell responses to both GAD and IA-2 were seen before therapy and once on reduction of high cortisone dosages when the patient showed signs of clinical deterioration. Cytokine profiles showed increased IFN-γ production after stimulation with GAD or IA-2 suggesting increased activation of T(H)1 cells. Conclusion - Immunosuppressive therapy - even with extremely high doses of 500 mg a day - does not lead to the reduction of antibody concentrations in the periphery nor to a switch in epitope recognition of such antibodies despite clinical improvement. The amount of T cell reactivity to various antigens, however, may be a useful marker to monitor the effectiveness of immunotherapy.

AB - Objectives - Humoral and cellular immune reactivity are reported for two neuroendocrine autoantigens - glutamic acid decarboxylase (GAD) and the protein tyrosine phosphatase IA-2 - in a patient with the autoimmune type of stiff-man syndrome and insulin dependent diabetes (IDDM). Methods - Antibodies and T cell proliferation against GAD and IA-2 and cytokine release of antigen stimulated T cells (IFN-γ) were determined before and several times during immunosuppressive therapy with prednisolone. Results - Raised GAD antibodies against full length GAD65 or chimeric constructs were detected before therapy and they remained at a high concentration despite a marked clinical improvement during cortisone treatment. Antibodies to IA-2 were undetectable, but weak T cell responses to both GAD and IA-2 were seen before therapy and once on reduction of high cortisone dosages when the patient showed signs of clinical deterioration. Cytokine profiles showed increased IFN-γ production after stimulation with GAD or IA-2 suggesting increased activation of T(H)1 cells. Conclusion - Immunosuppressive therapy - even with extremely high doses of 500 mg a day - does not lead to the reduction of antibody concentrations in the periphery nor to a switch in epitope recognition of such antibodies despite clinical improvement. The amount of T cell reactivity to various antigens, however, may be a useful marker to monitor the effectiveness of immunotherapy.

KW - Autoantibodies

KW - Prednisolone therapy

KW - Stiff-man syndrome

KW - T cell reactivity

UR - http://www.scopus.com/inward/record.url?scp=0031874058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031874058&partnerID=8YFLogxK

M3 - Article

C2 - 9703171

AN - SCOPUS:0031874058

VL - 65

SP - 204

EP - 208

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -